Tags

Type your tag names separated by a space and hit enter

Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Cell Host Microbe. 2020 Jun 10; 27(6):870-878.CH

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.

Links

PMC Free PDF

Authors+Show Affiliations

Park A
Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Iwasaki A
Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA; Department of Molecular Cellular and Developmental Biology, Yale University School of Medicine, New Haven, CT, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. Electronic address: akiko.iwasaki@yale.edu.

MeSH

AnimalsAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsHumansImmune EvasionInterferon Type IInterferonsPandemicsPneumonia, ViralRecombinant ProteinsSARS-CoV-2Signal TransductionInterferon Lambda

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

32464097

Citation

Park, Annsea, and Akiko Iwasaki. "Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19." Cell Host & Microbe, vol. 27, no. 6, 2020, pp. 870-878.
Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe. 2020;27(6):870-878.
Park, A., & Iwasaki, A. (2020). Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host & Microbe, 27(6), 870-878. https://doi.org/10.1016/j.chom.2020.05.008
Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe. 2020 Jun 10;27(6):870-878. PubMed PMID: 32464097.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. AU - Park,Annsea, AU - Iwasaki,Akiko, Y1 - 2020/05/27/ PY - 2020/5/29/pubmed PY - 2020/6/20/medline PY - 2020/5/29/entrez SP - 870 EP - 878 JF - Cell host & microbe JO - Cell Host Microbe VL - 27 IS - 6 N2 - Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19. SN - 1934-6069 UR - https://www.unboundmedicine.com/medline/citation/32464097/Type_I_and_Type_III_Interferons___Induction_Signaling_Evasion_and_Application_to_Combat_COVID_19_ DB - PRIME DP - Unbound Medicine ER -